Imago BioSciences (IMGO) Stock Analysis

What Imago BioSciences does

Imago BioSciences, Inc. is a clinical-stage biopharmaceutical firm specializing in the identification and advancement of small molecule product candidates. These candidates are designed to inhibit lysine-specific demethylase 1 (LSD1), an enzyme integral to the generation of blood cells within the bone marrow. The company's flagship therapeutic, bomedemstat, is presently undergoing Phase II clinical trials. It is being developed as a potential treatment for myeloproliferative neoplasms, a class of chronic bone marrow malignancies that includes conditions such as myelofibrosis, essential thrombocythemia, and polycythemia vera. Established in 2012, Imago BioSciences is headquartered in South San Francisco, California.

Key metrics

ETFs linked to IMGO

Broad-market and Healthcare sector ETFs an investor holding Imago BioSciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IMGO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Imago BioSciences?

Imago BioSciences trades under the ticker IMGO on NASDAQ.

Which exchange is IMGO listed on?

IMGO is listed on NASDAQ.

What sector does Imago BioSciences operate in?

Imago BioSciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IMGO in a portfolio?

PortView shows IMGO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.